Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Micolette is a rectal micro-enema developed by AFT Pharmaceuticals and Hyloris Pharmaceuticals for the treatment of constipation and for bowel cleansing prior to rectal examinations. It is a combination product containing sodium citrate, sodium lauryl sulfoacetate, and sorbitol. The mechanism of action involves osmotic and surfactant properties: sodium citrate and sorbitol act as osmotic laxatives by drawing water into the lower intestine to soften the stool, while sodium lauryl sulfoacetate serves as a wetting agent that reduces surface tension, allowing the liquid to penetrate the fecal mass. This localized action typically results in a bowel movement within 5 to 15 minutes. Micolette is positioned as a generic alternative to the established micro-enema product Microlax.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Micolette.